Cerebrolysin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Cerebrolysin (developmental code name FPF-1070) is a mixture of peptides purified from pig brains, including (and not limited to) brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).[1][2]

While cerebrolysin is used for stroke[3] and vascular dementia, there is insufficient evidence to support this use.[4] It is also sold as a nootropic.

There is some tentative evidence of a beneficial effect on cognitive function in people with vascular dementia,[5] possibly through decreased beta-amyloid deposition.[6] Cerebrolysin is widely used in Russia, Eastern Europe, China, and other post-Soviet and Asian countries.[7]

References[edit]

  1. ^ Windisch M, Gschanes A, Hutter-Paier B (1998). "Neurotrophic activities and therapeutic experience with a brain derived peptide preparation". J. Neural Transm. Suppl. 53: 289–98. PMID 9700665.
  2. ^ Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS (2012). "Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals". CNS Neurol Disord Drug Targets. 11 (1): 40–9. doi:10.2174/187152712799960781. PMID 22229324.
  3. ^ Ziganshina, Liliya Eugenevna; Abakumova, Tatyana; Vernay, Ludivine (April 21, 2017). "Cerebrolysin for acute ischaemic stroke". The Cochrane Database of Systematic Reviews. 4: CD007026. doi:10.1002/14651858.CD007026.pub5. ISSN 1469-493X. PMID 28430363.
  4. ^ Chen, N; Yang, M; Guo, J; Zhou, M; Zhu, C; He, L (31 January 2013). "Cerebrolysin for vascular dementia". The Cochrane Database of Systematic Reviews (1): CD008900. doi:10.1002/14651858.CD008900.pub2. PMID 23440834.
  5. ^ Chen, N; Yang, M; Guo, J; Zhou, M; Zhu, C; He, L (31 January 2013). "Cerebrolysin for vascular dementia". The Cochrane Database of Systematic Reviews (1): CD008900. doi:10.1002/14651858.CD008900.pub2. PMID 23440834.
  6. ^ Masliah E, Díez-Tejedor E (2012). "The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders". Drugs Today. 48 Suppl A: 3–24. doi:10.1358/dot.2012.48(Suppl.A).1739716 (inactive 2018-09-27). PMID 22514792.
  7. ^ Ziganshina, Liliya Eugenevna; Abakumova, Tatyana; Vernay, Ludivine (2017-04-21). "Cerebrolysin for acute ischaemic stroke". Cochrane Database of Systematic Reviews. 4: CD007026. doi:10.1002/14651858.CD007026.pub5. ISSN 1465-1858. PMID 28430363.